(4-Chloro-phenyl)-[4-(3-chloro-phenyl)-2-methoxy-quinolin-6-yl]-(5-mercapto-4-methyl-4H-[1,2,4]triazol-3-yl)-methanol | 406162-22-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: (4-Chloro-phenyl)-[4-(3-chloro-phenyl)-2-methoxy-quinolin-6-yl]-(5-mercapto-4-methyl-4H-[1,2,4]triazol-3-yl)-methanol
• 英文别名: 4-(3-chlorophenyl)-alpha-(4-chlorophenyl)-alpha-(5-mercapto-4-methyl-4H-1,2,4triazol-3-yl)-2-methoxy-6-quinolinemethanol；3-[(4-chlorophenyl)-[4-(3-chlorophenyl)-2-methoxyquinolin-6-yl]-hydroxymethyl]-4-methyl-1H-1,2,4-triazole-5-thione
• CAS: 406162-22-9
• 化学式: C₂₆H₂₀Cl₂N₄O₂S
• 分子量: 523.442
• InChiKey: KRSQUBLWBZEPQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4-Chloro-phenyl)-[4-(3-chloro-phenyl)-2-methoxy-quinolin-6-yl]-(5-mercapto-4-methyl-4H-[1,2,4]triazol-3-yl)-methanol 在 盐酸 、 硝酸 、 sodium nitrite 作用下， 以 四氢呋喃 为溶剂， 反应 48.25h， 生成 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(4-methyl-4H-1,2,4-triazol-3-yl)methyl]-2(1H)-quinolinone
  参考文献：
  名称：

  4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the Farnesyltransferase inhibitor ZARNESTRA ™

  摘要：

  Replacement of the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA(TM) series by a 4-methyl-1,2,4-triazol-3-yl group gave us compounds with similar structure-activity relationship profiles showing that this triazole is potentially a good surrogate to imidazole for farnesyltransferase inhibition. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.043
• 作为产物：
  描述：

  [2-Chloro-4-(3-chloro-phenyl)-quinolin-6-yl]-(4-chloro-phenyl)-methanone 在 正丁基锂 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 18.5h， 生成 (4-Chloro-phenyl)-[4-(3-chloro-phenyl)-2-methoxy-quinolin-6-yl]-(5-mercapto-4-methyl-4H-[1,2,4]triazol-3-yl)-methanol
  参考文献：
  名称：

  4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the Farnesyltransferase inhibitor ZARNESTRA ™

  摘要：

  Replacement of the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA(TM) series by a 4-methyl-1,2,4-triazol-3-yl group gave us compounds with similar structure-activity relationship profiles showing that this triazole is potentially a good surrogate to imidazole for farnesyltransferase inhibition. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.043
• 作为试剂：
  描述：

  正丁基锂 、 4-甲基-4H-3-巯基-1,2,4-三氮唑 、 (4-chlorophenyl)-[4-(3-chlorophenyl)-2-methoxyquinolin-6-yl]methanone 、 水 在 氮气 、 乙酸乙酯 、 magnesium sulfate 、 silica gel 、 cyclohexane, ethyl acetate 、 (4-Chloro-phenyl)-[4-(3-chloro-phenyl)-2-methoxy-quinolin-6-yl]-(5-mercapto-4-methyl-4H-[1,2,4]triazol-3-yl)-methanol 作用下， 以 四氢呋喃 为溶剂， 反应 1.75h， 以yielding 11.06 g (35%) of 4-(3-chlorophenyl)-α-(4-chlorophenyl)-α-(5-mercapto-4-methyl-4H-1,2,4triazol-3-yl)-2-methoxy-6-quinolinemethanol (intermediate 57), mp. >260° C.的产率得到(4-Chloro-phenyl)-[4-(3-chloro-phenyl)-2-methoxy-quinolin-6-yl]-(5-mercapto-4-methyl-4H-[1,2,4]triazol-3-yl)-methanol
  参考文献：
  名称：

  Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives

  摘要：

  本发明涉及以下式子(I)的化合物： 其中r，s，t，Y1-Y2，R1，R2，R3，R4，R5，R6和R7具有定义意义，具有法尼醇转移酶抑制活性；它们的制备、含有它们的组合物以及它们作为药物的用途。

  公开号：

  US07173040B2

文献信息

• Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties
  申请人：——

  公开号：US20040048882A1

  公开（公告）日：2004-03-11

  This invention comprises the novel compounds of formula (I) wherein r, s, t, Y 1 —Y 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 have defined meanings, having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.

  这项发明包括具有法尼醇转移酶抑制活性的式(I)的新化合物，其中r、s、t、Y1—Y2、R1、R2、R3、R4、R5、R6和R7具有定义的含义；它们的制备、含有它们的组合物以及它们作为药物的用途。
• US7173040B2
  申请人：——

  公开号：US7173040B2

  公开（公告）日：2007-02-06
• 4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the Farnesyltransferase inhibitor ZARNESTRA ™
  作者：Patrick Angibaud、Ashis K. Saha、Xavier Bourdrez、David W. End、Eddy Freyne、Patricia Lezouret、Geert Mannens、Laurence Mevellec、Christophe Meyer、Isabelle Pilatte、Virginie Poncelet、Bruno Roux、Gerda Smets、Jacky Van Dun、Marc Venet、Walter Wouters

  DOI：10.1016/j.bmcl.2003.09.043

  日期：2003.12

  Replacement of the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA(TM) series by a 4-methyl-1,2,4-triazol-3-yl group gave us compounds with similar structure-activity relationship profiles showing that this triazole is potentially a good surrogate to imidazole for farnesyltransferase inhibition. (C) 2003 Elsevier Ltd. All rights reserved.
• Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US07173040B2

  公开（公告）日：2007-02-06

  This invention comprises the compounds of formula (I): wherein r, s, t, Y1–Y2, R1, R2, R3, R4, R5, R6 and R7 have defined meanings, having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.

  本发明涉及以下式子(I)的化合物： 其中r，s，t，Y1-Y2，R1，R2，R3，R4，R5，R6和R7具有定义意义，具有法尼醇转移酶抑制活性；它们的制备、含有它们的组合物以及它们作为药物的用途。